TF Capital

AskGene Pharma is a biotechnology firm. It is developing novel cytokine prodrugs to address critical unmet medical needs in oncology and autoimmune disease. It is unlocking the full therapeutic potential of cytokine molecules with their innovative smart kine prodrug platform. It overcomes a number of significant challenges, providing a clear pathway to a range of next-generation cytokine therapies. They provide safer and better medicines for saving patients’ lives. They are equipped with the most advanced R&D facilities.

Yuesai Biotechnology is a cell therapy drug developer that uses human pluripotent stem cell technology. Yuesai Biotechnology develops stem cell therapy for neurodegenerative diseases, rare diseases, and tumors using its proprietary intellectual property rights of human pluripotent stem cell preparation, cultivation, differentiation, and gene editing technology platform.

UniXell develops cell therapies for the treatment of cancer and neurodegenerative disorders.

ChemSemi develops 5G chips and semiconductor technologies.

Hesguard is a medical device developer and producer of high-end implantable medical devices related to ophthalmic diseases.

Allorion Therapeutics is a small molecule therapeutic development company that focuses on cancer and autoimmune illnesses. Allorion operates two locations in Natick, Massachusetts, and Guangzhou, China.

Positive Sequence Biology is a biotech company with new gene system-based editing, focused on biotech innovation & breakthrough therapies.

Structure Therapeutics creates life-changing medicines for patients using advanced computational and structure-based technology. Our platform combines the latest advancements in computational chemistry, visualization of molecular interactions, and data integration to design orally available, superior medicines that overcome current limitations in biologic and peptide drugs. We are advancing our clinical-stage pipeline of differentiated, efficacious and safe treatments focused on chronic diseases with high unmet need, including cardiovascular, metabolic and pulmonary conditions. At Structure, our team’s deep experience with complex biological targets and mechanisms, structure-based drug design, and global drug discovery and development enables our bold vision: to design and develop world-class medicines with tremendous patient impact and broad commercial opportunity.

Cellular Biomedicine Group is a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases utilizing proprietary cell therapy technologies. It is the result of the acquisition, transfer, commercialization, and advancement of thirty years of research and human treatment experience in cellular medicine. Its cellular research and development is the result of collaboration among scientists and doctors from the US, England, and China.

Coordination Pharmaceuticals is a drug development company that aims to address unmet medical needs and improve patient care. The NCP platform was pioneered by the lab of Professor Wenbin Lin at the University of Chicago. As a versatile technology platform, NCP components can be purposefully chosen to synergize with and enhance currently existing therapies. CPI products are especially potent in combination with checkpoint blockade inhibitors by increasing T cell infiltration into lowly immunogenic solid tumors.

CytoLynx Therapeutics is a R&D and commercial platform leveraging Cytovia’s unique technologies and product pipeline.

Etern is developing small molecule drugs for protein liquid-liquid phase separation, using the LLPS platform for AI-enabled target discovery, high-throughput screening, and optimization. This could open new treatment strategies for major diseases.

Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.

Newsoara is a biomedical technology developer that specializes in the development of medical devices.

Regor Therapeutics is a clinical-stage company dedicated to the discovery and development of innovative and clinically differentiated medicines by leveraging the proprietary CARD (Computer Accelerated Rational Discovery) Platform, seamlessly integrating structural biology, computational chemistry, therapeutic biology, medicinal chemistry, and clinical development. Regor has assembled a world-class scientific team and demonstrated high efficiency in producing best- and first-in-class molecules.

SciNeuro Pharmaceuticals is a clinical-stage biotechnology company focused on developing groundbreaking therapies for neurodegenerative diseases. Since its founding in 2020, SciNeuro has built a portfolio of pipeline programs staged from discovery to clinical development by addressing three key disease-driving mechanisms of neurodegeneration – neurovascular inflammation, proteinopathy, and immune response. The company aims to develop disease-modifying treatment options for Alzheimer’s disease, Parkinson’s disease, and other devastating CNS diseases.

Hanyu Medical is one of the first domestic companies to develop, produce, and sell transcatheter mitral valve repair devices. At present, the company’s core product is Valve Clamp, a mitral valve interventional device, which is used for minimally invasive interventional treatment of mitral valve regurgitation diseases.

Ranok Therapeutics is a biotechnology company that is developing a novel targeted protein degradation technology to aid in the discovery and development of novel therapeutics. Ranok's TPD technology engages various underlying biological processes and outperforms competing TPD approaches. Ranok's pipeline contains both well-validated and novel drug targets involved in cancer and other diseases with significant unmet medical needs. Ranok is dedicated to developing the next generation of cancer therapies that are both safer and more effective.

Oceanus Plus focuses on the development of clinical research products and has independent intellectual property rights.

EOC Pharma is an integrated biopharmaceutical company that is focused on the manufacturing, development and commercialization of innovative global oncology products in China. They have adopted a licensing model in order to build EOC’s innovative pipeline by plugging their partner’s molecule into EOC’s “core engine” of local manufacturing, clinical development, regulatory filing, and commercialization. The company has a pipeline of seven novel products from global biopharmaceutical partners that are potentially first- and best-in-class. Until now, EOC has obtained four Class I innovative drug CTA approvals and initiated clinical studies of four lead products in China.,EOC has a team of entrepreneurs and consultants with overseas background that boasts of first-class pharmaceutical R&D expertise as well as rich industry experience. The company owns an 8,000 square meter cGMP manufacturing facility in Taizhou, China Medical City and has offices in Shanghai, Beijing, Hong Kong and Los Angeles. EOC will leverage forward-looking licensing which will provide product opportunities to their integrated platform, generating a highly strategic portfolio. Ultimately, this will position EOC at the top of oncology innovation in China.

Founded in 2015, Shenzhen Tisenc Medical Devices Co., Ltd. is a Sino-foreign joint venture. Located in Shenzhen Guangdong, Tisenc Medical devices delicate in the developing, manufacturing and global sales of chemiluminescence Immunology (CLIA) systems. The company provides the product of CLIA system, high-level POCT system, and molecular diagnostics solutions. Tisenc now has R&D labs, GMP factory, Instrument factory for totally over 16000 square meters space. And fully intellectual property right for product and technologies, the company is fully independent for the R&D and production of a product.

GeneQuantum Healthcare (Suzhou) Co., Ltd. is a high-tech company that focuses on the research and development of innovative Bio-therapeutics. GeneQuantum was founded in August 2013 at Suzhou Industrial Park, and has built-up a world-class bio-conjugation technology platform, focusing on developing series of next generation anti-tumor Antibody-Drug-Conjugates (ADCs) with best-in-class potential. Securing this round of financing will significantly promote the development of current ADC candidates towards IND filling in both US and China, meanwhile further expanding the company's product pipeline.

Abbisko Therapeutics is a drug company dedicated to innovative drug research and development. The company is founded by a group of seasoned drug hunters with rich research and managerial experience in top pharmaceutical companies globally and in China.

Zion is a leading drug discovery platform that develops "me-better" drugs that address true unmet needs.

Antengene is a developer of biotechnology and bio-pharmaceuticals intended to provide medicine treatment for tumor.The company focuses on providing patients with innovative anti-tumor and anti-cancer therapies through new drug development, clinical research and drug production, enabling physicians to meet unmet medical needs in Asia.

GenFleet Therapeutics is a developer and researcher of molecular pharmaceuticals targeting cancer treatments. The company specializes in developing innovative molecular-level pharmaceuticals and antibody drugs targeting various cancer systems, providing effective medical solutions to reactivate tumor-specific immune responses and to mobilize the body's own immune system.

Xgene Pharmaceutical is a late-clinical stage, venture-backed international company that uses proprietary linker technology to develop novel, multimodal conjugated molecules for the treatment of neurological disorders. Current programs are aimed at increasing the efficacy and tolerability of pain medications.

Eccogene is a clinical stage biopharmaceutical company that provides therapeutic solutions to address unmet medical needs. They offer services in the discovery and development of translational medicine in metabolic and immune-related diseases.

Alpha Biopharma is supported by the domestic and foreign famous funds, and committed to the clinical development of global innovator drug. The company collaborates with the large-scale international drug companies to ensure the preliminary research and development of the product is solid and reliable. By using the powerful scientific consultant and management team and developing the optimization strategy for innovative drug development, the company lay emphasis on the multi-dimensional layout: research and development/market/intellectual property protection. The specifictest operation and business development are collaborated with the international/domestic topCRO/CMO/hospital/institute, and ensure the program is rational and orderly implementation by using the company’s impeccable project management system.

Founded in 2015, Shenzhen Tisenc Medical Devices Co., Ltd. is a Sino-foreign joint venture. Located in Shenzhen Guangdong, Tisenc Medical devices delicate in the developing, manufacturing and global sales of chemiluminescence Immunology (CLIA) systems. The company provides the product of CLIA system, high-level POCT system, and molecular diagnostics solutions. Tisenc now has R&D labs, GMP factory, Instrument factory for totally over 16000 square meters space. And fully intellectual property right for product and technologies, the company is fully independent for the R&D and production of a product.

Founded in 2015, XpectVision Technology is a high-tech company committed to disruptive and innovative technology development. XpectVision has been trailblazing in the field of photon-counting X-ray imaging. Also the company is poised to be the leader of other futuristic imaging technology, including high-speed high-definition imaging chip.

Xgene Pharmaceutical is a late-clinical stage, venture-backed international company that uses proprietary linker technology to develop novel, multimodal conjugated molecules for the treatment of neurological disorders. Current programs are aimed at increasing the efficacy and tolerability of pain medications.

Antengene is a developer of biotechnology and bio-pharmaceuticals intended to provide medicine treatment for tumor.The company focuses on providing patients with innovative anti-tumor and anti-cancer therapies through new drug development, clinical research and drug production, enabling physicians to meet unmet medical needs in Asia.

GeneQuantum Healthcare (Suzhou) Co., Ltd. is a high-tech company that focuses on the research and development of innovative Bio-therapeutics. GeneQuantum was founded in August 2013 at Suzhou Industrial Park, and has built-up a world-class bio-conjugation technology platform, focusing on developing series of next generation anti-tumor Antibody-Drug-Conjugates (ADCs) with best-in-class potential. Securing this round of financing will significantly promote the development of current ADC candidates towards IND filling in both US and China, meanwhile further expanding the company's product pipeline.

Abbisko Therapeutics is a drug company dedicated to innovative drug research and development. The company is founded by a group of seasoned drug hunters with rich research and managerial experience in top pharmaceutical companies globally and in China.

Asieris Pharmaceuticals is a Chinese biotech company focusing on therapeutic areas in oncology and multidrug-resistant infections.

Hua Medicine is a clinical-stage, innovative drug development company in China, focused on novel therapies for the treatment of diabetes and CNS disorders. Founded by pharma industry veterans and funded by a premier group of international VC investment firms such as Fidelity Asia, Fidelity Biosciences, ARCH Ventures, Venrock, SAIL and WuXi Ventures, the company has in-licensed from major pharma, world-wide rights to a potential best-in-class, oral drug for the treatment of Type 2 Diabetes which utilizes a novel mechanism of action.

Zai Lab is an innovative biopharmaceutical company based in Shanghai focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. Since their founding in 2014, their experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates. They see theirselves as the trusted partner of choice for global biopharmaceutical companies seeking to access the Chinese market. Leveraging their team’s extensive global drug development expertise, combined with their demonstrated understanding of the pharmaceutical industry, the increasingly favorable clinical and regulatory environment in China and their in-house manufacturing capabilities, they plan to continue to secure relationships with global pharmaceutical companies to further expand their pipeline and foster innovation in China. Their team is passionate about bringing transformative new medicines to patients. Their vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing their partner’s and their own products in China and around the world. To that end, they have built manufacturing capabilities to support the clinical and commercial production of their drug candidates in China, and they expect to have further clinical production capabilities in the near future. Their team is planning to establish a specialized commercial team to support marketing of their products in China and beyond, and they are expanding their discovery efforts both internally and through collaborations with leading academic institutions.

Ark Biosciences is a biopharmaceutical company that is dedicated to the discovery and development of innovative therapeutics to address unmet medical need, especially in the area of respiratory viral infection and viral hepatitis, for global and China market. We strive to build a science-driven biopharmaceutical company that aims to be a leader in antiviral drug discovery and development. To achieve so, we aspire for the excellence of science and be innovative. We operate with a razor-sharp focus and aggressiveness with a timely and cost efficient manner. We create a healthy and rewarding work environment for employees, and seek a superior rate of return for investors and partners.

Hua Medicine is a clinical-stage, innovative drug development company in China, focused on novel therapies for the treatment of diabetes and CNS disorders. Founded by pharma industry veterans and funded by a premier group of international VC investment firms such as Fidelity Asia, Fidelity Biosciences, ARCH Ventures, Venrock, SAIL and WuXi Ventures, the company has in-licensed from major pharma, world-wide rights to a potential best-in-class, oral drug for the treatment of Type 2 Diabetes which utilizes a novel mechanism of action.

CANbridge Pharmaceuticals is a bio-pharmaceutical company accelerating development and commercialization of specialty healthcare products for serious and critical medical conditions in China and North Asia (Korea and Taiwan). CANbridge develops partnerships with Western bio-pharmaceutical companies with clinical-stage pharmaceutical, medical device or diagnostic products that are either unavailable in China/North Asia or address medical needs that are underserved in the region. CANbridge also licenses or obtains exclusive rights to commercialize drug and device products that are approved in their home markets for commercialization in China and North Asia.

Zai Lab is an innovative biopharmaceutical company based in Shanghai focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. Since their founding in 2014, their experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates. They see theirselves as the trusted partner of choice for global biopharmaceutical companies seeking to access the Chinese market. Leveraging their team’s extensive global drug development expertise, combined with their demonstrated understanding of the pharmaceutical industry, the increasingly favorable clinical and regulatory environment in China and their in-house manufacturing capabilities, they plan to continue to secure relationships with global pharmaceutical companies to further expand their pipeline and foster innovation in China. Their team is passionate about bringing transformative new medicines to patients. Their vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing their partner’s and their own products in China and around the world. To that end, they have built manufacturing capabilities to support the clinical and commercial production of their drug candidates in China, and they expect to have further clinical production capabilities in the near future. Their team is planning to establish a specialized commercial team to support marketing of their products in China and beyond, and they are expanding their discovery efforts both internally and through collaborations with leading academic institutions.

Shanghai Sanyou Medical Co., Ltd is a corporation that is therapy innovation oriented and devotes to the R&D , manufacture and sales of independently innovative orthopedics implants . The headquarter is located in the Medical Apparatus Garden of Zhangjiang Hi-Tech Park , Shanghai . In September 2010 , a senior international management team finished the corporation restructuring and set up a brand new management mechanism to become a valuable and sustainable company .